Pepita Jean
Payments from drug & device makers
Across 70 payments — averaging $106.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$4K
- Sanofi-aventis U.S. LLC$902
- CTI Biopharma Corp.$700
- Astellas Pharma US Inc$284
- Adaptive Biotechnologies Corporation$242
- Johnson & Johnson$158
- plus $889 from 14 others
What the payments were for
- Consulting fees$2,70036%
- Speaking & faculty fees$7009%
- Travel & lodging$1,26717%
- Food & beverage$2,52734%
- Education$2764%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 12 | $4,295 |
| Sanofi-aventis U.S. LLC | 25 | $902 |
| CTI Biopharma Corp. | 1 | $700 |
| Astellas Pharma US Inc | 6 | $284 |
| Adaptive Biotechnologies Corporation | 4 | $242 |
| Johnson & Johnson | 2 | $158 |
| Novo Nordisk | 1 | $125 |
| Sobi, Inc | 1 | $124 |
| Gamida Cell Inc. | 1 | $109 |
| Legend Biotech USA Inc. | 3 | $95 |
| Gilead | 1 | $95 |
| Merck | 4 | $78 |
| Amarin Pharma, Inc. | 1 | $70 |
| Daiichi Sankyo Inc. | 2 | $51 |
| EMD Serono, Inc. | 1 | $50 |
| Foundation Medicine, Inc. | 1 | $25 |
| Pfizer | 1 | $21 |
| Dynavax Technologies Corporation | 1 | $16 |
| Tersera Therapeutics LLC | 1 | $16 |
| Myovant Sciences Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,469 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 15 | $31 |
Paid to pharmacies, not to this prescriber.
Other family in Miami
- Stephanie MompointMiami$4.5M
- Itsel Cardenas RamonMiami$1M
- Patrick SzarazMiami$327K
- Yamila MelendezMiami$212K
- Suzan RosenMiami$129K
- Felipe NovoaMiami$110K
- Pamela DudkiewiczMiami$89K
- Stacy FeemsterMiami$51K
- John HuffakerVenice$8M
- Miguel TrujilloMiami Gardens$4.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.